Lecanemab | ||||||
---|---|---|---|---|---|---|
Category | Placebo (n = 245) n (%) | 2.5 mg/kg Biweekly (n = 52) n (%) | 5 mg/kg Monthly (n = 51) n (%) | 5 mg/kg Biweekly (n = 92) n (%) | 10 mg/kg Monthly (n = 253) n (%) | 10 mg/kg Biweekly (n = 161) n (%) |
Any TEAE | 216 (88.2) | 46 (88.5) | 48 (94.1) | 81 (88.0) | 238 (94.1) | 39 (86.3) |
Treatment-related TEAE | 65 (26.5) | 23 (44.2) | 25 (49.0) | 31 (33.7) | 135 (53.4) | 76 (47.2) |
Serious adverse event | 43 (17.6) | 10 (19.2) | 4 (7.8) | 16 (17.4) | 31 (12.3) | 25 (15.5) |
Deaths | 2 (0.8) | 2 (3.8) | 0 | 1 (1.1) | 2 (0.8) | 0 |
AE leading to discontinuation | 15 (6.1) | 7 (13.5) | 4 (7.8) | 10 (10.9) | 47 (18.6) | 24 (14.9) |
ARIA-E | 2 (0.8) | 1 (1.9) | 1 (2.0) | 3 (3.3) | 25 (9.9) | 16 (9.9) |
ApoE4-positive (n = 436) | 2 (1.1) | 1 (2.6) | 1 (2.5) | 3 (3.6) | 23 (10.2) | 7 (14.3) |
ApoE4-negative(n = 112) | 0 | 0 | 0 | 0 | 2 (7.1) | 9 (8.0) |